Ocular Therapeutix™ and Regeneron Enter Into Strategic Collaboration to Develop Sustained Release Formulation of Aflibercept for the Treatment of Wet AMD and Other Serious Retinal Diseases
Sustained Release Formulation Has Potential to Significantly Advance Current Standard of Care by Reducing Injection Frequency in the Treatment of Wet AMD
Ocular Therapeutix Eligible to Receive up to
Company to Host Conference Call Today at
Under the terms of the agreement,
Upon exercising of the option,
“We have made considerable progress in developing our protein drug
delivery platform at
About Wet AMD and Other VEGF-Associated Retinal Diseases
Wet age-related macular degeneration (wet AMD) is characterized by loss of vision caused by degeneration of the central portion of the retina. Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, causes retinal degeneration and can lead to severe and rapid loss of vision. Wet AMD is the leading cause of blindness in individuals aged 50 years or older.
Retinal vein occlusion (RVO) is a sight-threatening disorder resulting from the blockage of one of the veins carrying blood out of the retina. In RVO, the blockage of a retinal vein can lead to poor blood circulation, low oxygen and sometimes inflammation in the eye. A blocked vein will leak its contents of blood and fluid. Bleeding within the retina and swelling from the fluid can result in macular edema.
Diabetic macular edema (DME) is a complication of diabetes caused by fluid accumulation in the macula, or central portion of the eye. When the macula begins to fill with fluid, the ability of those cells to sense light is impaired, causing blurred vision that can be severe. Diabetic macular edema affects up to 30% of people who have had diabetes for 20 years or more, and if untreated, 20 to 30% of people who have it will experience moderate visual loss.
The global market for anti-VEGF drugs is over
Conference Call & Webcast Information
Members of the
The live webcast and accompanying slide presentation can be accessed by
visiting the investor section of the Company’s website at
investors.ocutx.com. Please connect at least 15 minutes prior to the
live webcast to ensure adequate time for any software download that may
be needed to access the webcast. Alternatively, please call 844-464-3934
(U.S.) or 765-507-2620 (International) to listen to the conference call.
The conference ID number for the live call will be 98223266. An archive
of the webcast will be available until
Any statements in this press release about future expectations, plans
and prospects for the Company, including statements about the potential
benefits and future operation of the collaboration with Regeneron,
including any potential future payments thereunder, the ongoing
development of the Company’s sustained release hydrogel depot
technology, the development and regulatory status of the Company’s other
product candidates, such as the Company’s expectations and plans
regarding regulatory submissions for and the timing and conduct of
clinical trials of DEXTENZA™ for post-surgical ocular inflammation and
pain, including our expectations regarding the NDA filed with the
Ocular Therapeutix, Inc.
Chief Financial Officer
Burns McClellan on behalf of Ocular Therapeutix
Steve Klass, 212-213-0006
Ocular Therapeutix, Inc.
Vice President of Sales and Marketing